A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Rhenium (186Re) obisbemeda (Primary)
- Indications Meningeal carcinomatosis
- Focus Adverse reactions
- Acronyms ReSPECT-LM
- Sponsors Plus Therapeutics
- 14 Aug 2024 According to a Plus Therapeutics media release, the company plans to complete ReSPECT-LM Phase 1 single administration trial and determine the recommended Phase 2 dose.
- 14 Aug 2024 According to a Plus Therapeutics media release, the company has submitted a new clinical protocol to the U.S. Food and Drug Administration (FDA), under its active Investigational New Drug application (IND 153715) for a Phase 1 study to evaluate multiple administrations of Rhenium (186Re) Obisbemeda for the treatment of patients with LM.
- 12 Aug 2024 According to a Plus Therapeutics media release, trial is funded in part, by a 3-year, $17.6 million grant by the Cancer Prevention & Research Institute of Texas.